| Sep 23 |
Should You Be Confident in the Growth Potential of Natera (NTRA)?
|
| Sep 16 |
ESMO 2024: Natera showcases chemotherapy prediction benefit of cDNA test
|
| Sep 16 |
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
|
| Sep 14 |
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
|
| Sep 11 |
Natera (NTRA) Continued its Incremental Strong Results
|
| Sep 9 |
DNA Testing Stock Taps AI Amid 85% Surge
|
| Sep 9 |
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
|
| Sep 6 |
Peering Into Natera's Recent Short Interest
|
| Sep 6 |
What Makes Natera (NTRA) an Investment Bet?
|
| Sep 3 |
Natera (NTRA) Rose After Revenues And Profit Margins Beat Estimates
|
